News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biothera Release: Imprime PGG in Combination With Monoclonal Antibody Therapy Achieves 64% Complete Response Rate in Chronic Lymphocytic Leukemia Patients


12/10/2012 10:14:48 AM

EAGAN, Minn.--(BUSINESS WIRE)--All subjects in a phase 1 study of high risk, chronic lymphocytic leukemia responded to the combination therapy of Imprime PGG®, alemtuzumab (Campath®) and rituximab (Rituxan®) with 64% achieving a complete response, according to data presented this past weekend at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, GA.

Read at BioSpace.com


comments powered by Disqus
Biothera
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES